Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study

Clinical trials indicate that amifostine may confer protection on various normal tissues without attenuating anti-tumor response. When administered prior to chemotherapy or radiotherapy, it may provide a broad spectrum of cytoprotection including against alkylating drugs. The mechanism of protection...

Full description

Bibliographic Details
Main Authors: C.A. De Souza, G. Santini, G. Marino, S. Nati, A.M. Congiu, A.C. Vigorito, E. Damasio
Format: Article
Language:English
Published: Associação Brasileira de Divulgação Científica 2000-07-01
Series:Brazilian Journal of Medical and Biological Research
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2000000700009